---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000155"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:42:31.391878+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Aprea Therapeutics reports Dec 31, 2024 cash balance of $22.8M

## Summary
- Cash and cash equivalents of $22.8M as of December 31, 2024 (preliminary, unaudited).
- Disclosed via corporate presentation posted to company website on January 13, 2025.
- Balance subject to completion of fiscal 2024 year-end financial statements.
- No other financial results or guidance provided in the presentation.

## SEC filing metadata
- accession: 0001558370-25-000155
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837025000155/0001558370-25-000155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837025000155/apre-20250113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000155
- JSON: https://secwatch.observer/filing/0001558370-25-000155.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.